Thursday, 27 January 2022

Australia's most trusted
source of pharma news

Thursday, 27 January 2022

Alzheimer's in the spotlight

Posted 30 November 2021 AM

A white paper commissioned by Biogen has made 32 recommendations to improve treatment for Alzheimer's Disease (AD), including training nurses and pathology centres to administer disease modifying therapies (DMTs) if and when they become available.

Information resources about DMTs for primary care providers to support them should also be developed, the paper suggested. Biogen's Aduhelm is currently before the TGA, and the company hopes to hear the outcome in the first half of 2022.

To see the whole article, please login

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.